See Local News
Get Balanced News From Your U.S. State.
See Local News
See all locals

EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported

Posted on AllSides July 10th, 2023
From The Center
REUTERS/George Frey/File Photo

The European Medicines Agency (EMA) is investigating Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm.

Shares of the Danish drugmaker fell 1% on Monday following the news.

An EMA safety committee is looking into adverse events raised by the Icelandic Medicines Agency, including two cases of suicidal thoughts in those who used Ozempic, which contains the active ingredient semaglutide, and Saxenda, the regulator said.

Another patient on Saxenda, Novo's earlier and less effective weight-loss...

Read full story

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right